Infectious diseases continue to be one of the largest threats to global health. Novel medical approaches for anti-infectives - active against infections caused by bacteria (antibiotics), viruses (antivirals), fungi (antifungals) and parasites (including antimalarials) - are urgently needed to meet challenges such as antimicrobial resistances.
Hamburg`s universities and research institutes focus on the exploration of disease mechanisms and new targets in this field. Additionally, industrial partners in Northern Germany are specialized on the technological validation of novel therapeutic approaches and provide a starting point for promising drug development according to industrial standards. The BRIDGE 53 is as a collaboration platform to provide sustained access to expertise and resources from industrial partners to help academics access early stage drug discovery and development capabilities. Our goal: Stimulation for the formation of new companies and development of therapies with much needed patient benefit in the field of infectious diseases.
The BRIDGE 53 includes research institutions and industry partners in Hamburg to accelerate drug development and knowledge transfer for anti-infectives as well as adjacent research fields. We bring scientists, industry and company building expertise together to efficiently deliver pre-clinical concepts to the marketplace.
The city of Hamburg and its port is Germany`s gateway to the world. Setting sail for new collaboration formats, the name BRIDGE 53 evolved from Hamburg’s latitude coordinates (53°34'31.15"N) and contributes to its long, prestigious history for local coordination of global perspectives.